Dopamine agonists (DAs) are usually used as first line treatment in prolactinomas. Some
tumors do not normalize prolactin levels under treatment and demonstrate a more …

Abstract Background/Aims: Prolactin (PRL) secretion and its gene expression are inhibited
by dopamine. Prolactinomas are the most common secreting pituitary adenomas, and …

Aim to assess the prevalence of the known factors that contribute to DA resistance (male
gender, younger age at diagnosis, large tumours, the invasiveness of the tumour) among …

Methods This is a retrospective, single-center study conducted at an academic quaternary-
care center. Immunohistochemical (IHC) analysis was performed on 16 specimens from …

Objective Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in
responsive prolactinoma. However, several cases have shown resistance to dopamine …

Dopamine receptor agonists (DAs) can reduce hormone release and tumor mass in the
majority of prolactinomas, whereas such effects are controversial in clinically nonfunctioning …

Purpose The dopamine agonists (DA) have been used widely to treat prolactinomas.
However, it is difficult to predict whether the patient will be responsive to DA treatment …

Background The treatment of dopamine agonists (DA) resistant prolactinomas remains a
formidable challenge, as the mechanism of resistance is still unclear, and there are currently …

Dopamine (DA)-agonist targeting of the DA D2 receptor (D2R) in prolactinomas is the first-
line treatment choice for suppression of prolactin and induction of tumor shrinkage …

Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …